Penumbra Inc PEN
We take great care to ensure that the data presented and summarized in this overview for Penumbra Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PEN
View all-
Black Rock Inc. New York, NY4.26MShares$1.2 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.65MShares$1.03 Billion0.02% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.5MShares$421 Million2.36% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.27MShares$356 Million0.03% of portfolio
-
State Street Corp Boston, MA1.2MShares$339 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL883KShares$249 Million0.55% of portfolio
-
Rtw Investments, LP New York, NY862KShares$243 Million3.34% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il734KShares$207 Million0.03% of portfolio
-
Baillie Gifford & CO730KShares$206 Million0.14% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD707KShares$199 Million0.1% of portfolio
Latest Institutional Activity in PEN
Top Purchases
Top Sells
About PEN
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Insider Transactions at PEN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 18
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
81
-0.12%
|
$21,951
$271.14 P/Share
|
Feb 18
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
1,840
+2.69%
|
-
|
Feb 18
2025
|
Lambert Shiu Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
95
-0.3%
|
$25,745
$271.14 P/Share
|
Feb 18
2025
|
Lambert Shiu Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,510
+4.55%
|
-
|
Feb 18
2025
|
Maggie Yuen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
81
-0.47%
|
$21,951
$271.14 P/Share
|
Feb 18
2025
|
Maggie Yuen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,840
+9.6%
|
-
|
Feb 14
2025
|
Surbhi Sarna Director |
BUY
Grant, award, or other acquisition
|
Direct |
744
+16.73%
|
-
|
Feb 14
2025
|
Janet Leeds Director |
BUY
Grant, award, or other acquisition
|
Direct |
744
+10.95%
|
-
|
Feb 14
2025
|
Thomas Wilder Director |
BUY
Grant, award, or other acquisition
|
Direct |
744
+40.86%
|
-
|
Feb 14
2025
|
Arani Bose Director |
BUY
Grant, award, or other acquisition
|
Direct |
744
+0.22%
|
-
|
Feb 14
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
780
+1.19%
|
-
|
Feb 14
2025
|
Bridget O'Rourke Director |
BUY
Grant, award, or other acquisition
|
Direct |
744
+11.69%
|
-
|
Feb 14
2025
|
Harpreet Grewal Director |
BUY
Grant, award, or other acquisition
|
Direct |
744
+7.43%
|
-
|
Feb 14
2025
|
Lambert Shiu Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
640
+2.08%
|
-
|
Feb 14
2025
|
Lambert Shiu Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,525
+13.3%
|
$99,550
$22.04 P/Share
|
Feb 14
2025
|
Maggie Yuen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
780
+4.8%
|
-
|
Feb 14
2025
|
Don W. Kassing Director |
BUY
Grant, award, or other acquisition
|
Direct |
744
+34.56%
|
-
|
Jan 03
2025
|
Harpreet Grewal Director |
SELL
Open market or private sale
|
Direct |
167
-1.92%
|
$40,247
$241.28 P/Share
|
Jan 02
2025
|
Don W. Kassing Director |
SELL
Open market or private sale
|
Direct |
170
-20.36%
|
$40,460
$238.84 P/Share
|
Dec 26
2024
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
1,350
+2.07%
|
$29,700
$22.04 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 27.8K shares |
---|---|
Exercise of conversion of derivative security | 16.1K shares |
Payment of exercise price or tax liability | 3.9K shares |
---|---|
Open market or private sale | 139K shares |
Bona fide gift | 69.9K shares |